Heidi Savage

<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd et al. · Clinical Cancer Research · 2009 · 470 citations

Molecular Biomarker Analyses Using Circulating Tumor Cells

Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke et al. · PLoS ONE · 2010 · 294 citations · Full text

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Jie Lin, Deepak Sampath, Michelle Nannini et al. · Clinical Cancer Research · 2013 · 292 citations

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Jill M. Spoerke, Steven Gendreau, Kimberly Walter et al. · Nature Communications · 2016 · 292 citations · Full text

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath et al. · Clinical Cancer Research · 2010 · 257 citations · Full text